|
Orthologous residues
|
|
HS1 (human): Y378‑p, HS1 (mouse): Y388‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
lymphoma, B cell lymphoma
|
|
Relevant cell lines - cell types - tissues:
COS (fibroblast), CV1 (fibroblast), WEHI-231 (B lymphocyte)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
monkey, mouse
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Syk (human)
|
pharmacological activator of upstream enzyme, activation of upstream enzyme, transfection of wild-type enzyme, genetic transfer of inducible upstream enzyme, phospho-motif antibody, modification site within consensus motif
|
kinase activation is co-transfection with Lyn
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
anti-IgM
|
|
|
|
increase
|
|
|
|
|
|
|
|
BCR-stimulated cell showed high level of phosphorylation
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization
|
|
Effect of modification (process):
apoptosis, altered
|